Home › Research › Biomarkers
Association of serum Apolipoprotein B with cerebrospinal fluid biomarkers of Alzheimer's pathology
Hu H, Tan L, Bi YL, Xu W, Tan L, Shen XN, Hou XH, Ma YH et al.. Annals of clinical and translational neurology, 2020-09-10
Topic: Amyloid, tau and blood-test diagnosis
Objective To examine whether apolipoprotein B (ApoB), apolipoprotein A-1 (ApoA1), or their ratio (ApoB/A1) were associated with early changes in cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) pathology in elderly adults with subjective cognitive decline (SCD). Methods This study included 507 objective cognitive normal participants from the Chinese Alzheimer's Biomarker and LifestylE (CABLE) database including 288 cognitive normal participants (CN) and 219 SCD. Multiple linear regression models were used to examine the associations of apolipoproteins with CSF AD biomarkers. Results Compared with control group, SCD participants with significant AD biological characteristics had lower ApoB levels (P = 0.0461). In total participants, lower level of serum ApoB was associated with decreases in CSF Aβ42 (P = 0.0015) and Aβ42/40 (P = 0.0081) as well as increases in CSF p-tau/Aβ42 (P < 0.0001) and t-tau/Aβ42 (P = 0.0013), independent of APOEɛ4 status. In further subgroup analysis, these associations were more significant in SCD participants (ApoB × Diagnose: P < 0.05). In addition, lower levels of ApoB were also found associated with increases in p-tau in the SCD subgroup (P = 0.0263). Furthermore, these protective associations were more significant in the overweight participants (ApoB × weight: P < 0.05). Results showed no association between ApoA1 and CSF biomarkers. Interpretation This study is the first to find protective associations of serum ApoB with CSF AD core biomarkers, especially in SCD individuals. It indicated that ApoB may be a potential biomarker for preclinical AD and may play different roles in different stages of AD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Hu, H., Tan, L., Bi, Y. L., Xu, W., Shen, X. N., Hou, X. H., et al. (2020). Association of serum Apolipoprotein B with cerebrospinal fluid biomarkers of Alzheimer's pathology. Annals of clinical and translational neurology. https://doi.org/10.1002/acn3.51153
Vancouver
Hu H, Tan L, Bi YL, Xu W, Shen XN, Hou XH, et al. Association of serum Apolipoprotein B with cerebrospinal fluid biomarkers of Alzheimer's pathology. Annals of clinical and translational neurology. 2020. doi:10.1002/acn3.51153. PMID: 32910550.
BibTeX
@article{hu2020-32910550,
author = {Hu, H. and Tan, L. and Bi, Y. L. and Xu, W. and Shen, X. N. and Hou, X. H. and Ma, Y. H. and others},
title = {{Association of serum Apolipoprotein B with cerebrospinal fluid biomarkers of Alzheimer's pathology}},
journal = {Annals of clinical and translational neurology},
year = {2020},
doi = {10.1002/acn3.51153},
pmid = {32910550},
url = {https://doi.org/10.1002/acn3.51153}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Objective To examine whether apolipoprotein B (ApoB), apolipoprotein A-1 (ApoA1), or their ratio (ApoB/A1) were associated with early changes in cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) pathology in elderly adults with subjective cognitive decline (SCD).
- Results Compared with control group, SCD participants with significant AD biological characteristics had lower ApoB levels (P = 0.0461).
- In total participants, lower level of serum ApoB was associated with decreases in CSF Aβ42 (P = 0.0015) and Aβ42/40 (P = 0.0081) as well as increases in CSF p-tau/Aβ42 (P < 0.0001) and t-tau/Aβ42 (P = 0.0013), independent of APOEɛ4 status.
- In further subgroup analysis, these associations were more significant in SCD participants (ApoB × Diagnose: P < 0.05).
- In addition, lower levels of ApoB were also found associated with increases in p-tau in the SCD subgroup (P = 0.0263).
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants507
- Evidence strengthLow
How this study scored 50/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 29 of the 58 points we could judge it on, which is 50 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Annals of clinical and translational neurology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 2 / 4 | 507 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 32910550) |
| Free to read | 2 / 2 | Free to read |
| Points | 29 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 29 of the 58 points we could judge it on is 50 out of 100. |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers
Also tagged “pathology”
9 studies in the library carry the topic tag “pathology”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 9 tagged studies.